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are shown in Figure 2. There is consider-
able uncertainty about all the centers’ true
ranks, which naturally arises from the high
degree of overlap of the confidence inter-
vals in Figure 1. We can only state with
confidence that center E is in the top half
(despite being ranked fourth) and center B
is in the bottom half; any further attempt at
detailed ranking is spurious. Table 1 pre-
sents the probabilities that centers near the
top or bottom of the league table truly are
the best or worst centers. No center re-
ceives more than 30% chance of being ei-
ther the winner or loser, although center P
turns out most likely to be the worst by a
small margin.
Such an analysis illustrates the grave
dangers of institutional ranking unless
there is clear heterogeneity among centers.
It also explains why there are generally
such radical changes in rankings from year
to year when profiling institutions. Presen-
tations that do not emphasize rankings,
such as the funnel plots of Stark and col-
leagues,3 are thus to be preferred.
David Spiegelhalter, PhD, Senior Scientist
MRC Biostatistics Unit
University Forvie Site
Cambridge, United Kingdom
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Reply to the Editor:
We thank Shuhaiber and Spiegelhalter for
their important questions regarding our ar-
ticle. Both questions relate to whether the
differences in institutional outcomes for
mortality after congenital heart surgery
demonstrated in our article represent true
differences in performance or were an ar-
tifact of our methodology, the Risk Adjust-
ment in Congenital Heart Disease
(RACHS-1) method.
Shuhaiber questions whether differ-
ences might have been mitigated had a
more comprehensive method of risk adjust-
ment been used. We agree that improved
methods of risk adjustment would have in-
creased our ability to compare outcomes
accurately. However, methods including
physiologic variables would have required
validation in a population with complex
congenital heart problems and would re-
quire extensive data collection. The
RACHS-1 method was derived from a for-
mal, consensus-based process and has been
validated with two diverse data sets, with
favorable performance characteristics. The
consensus committee that developed
RACHS-1 specifically sought to create a
method of risk adjustment useful to under-
stand group outcomes using data elements
that are frequently available. To clarify,
risk categories were incorporated into the
risk adjustment model as binary covariates,
which do not impose a linear or exponen-
tial relationship among categories. We
agree that although most centers in the
analysis had similar relative ranks across
risk categories or worse performance for
higher risk procedures, in 5 centers a sur-
prising pattern of worse performance for
higher risk performance was observed. Ex-
plorations by centers of why these patterns
emerged should include a search for un-
measured risk factors but should also eval-
uate more programmatic possibilities, such
as surgical referral patterns, location of
postoperative care, and so on.
Spiegelhalter questions whether ranking
institutions is an appropriate way to judge
relative performance. Although we agree in
general about the imprecision inherent in
using ranks, especially when numbers of
cases are small, we are attempting to guide
quality improvement efforts in a field
where considerable variability in institu-
tional surgical mortality has been demon-
strated by many investigators but annual
caseloads are small and are unlikely to in-
crease substantially. Although there may
be uncertainty about a center’s exact rank
or about how large a difference in ranks is
clinically important, program directors try-
ing to guide improvement efforts should
find it more useful to know their observed
rank than to be informed that their center’s
relative performance did not reach statisti-
cal significance.
We would like to emphasize that we
would never suggest “profiling” an institu-
tion on the basis of any single analysis,
especially one derived from administrative
data in a single calendar year. However,
these analyses may prove useful to illumi-
nate potential quality problems that need to
be explored further, preferably by the insti-
tution itself.
Kathy Jenkins, MD, MPH
Kimberlee Gauvreau, ScD
Department of Cardiology
Boston Children’s Hospital
300 Longwood Ave
Boston, MA 02115
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Symmetry aortic connector system
To the Editor:
I read with interest the article by Donsky
and associates1 in which they outlined sev-
eral misadventures with the Symmetry aor-
tic connector system (St Jude Medical, Inc,
St Paul, Minn). In our practice, we have an
extensive series of off-pump coronary ar-
tery bypass operations in which the Sym-
metry connector has been used. Although
the manufacturer has not recommended
any anticoagulation regimen postopera-
tively, my colleagues and I routinely ad-
minister clopidogrel postoperatively for 6
weeks.
We justified this therapy after we dem-
onstrated, at least by thrombelastography, a
relative state of hypercoagulation after off-
pump operations when compared with con-
ventional cardiopulmonary bypass.2 Fur-
thermore, after deployment of an
intracoronary stent, it is standard to pre-
scribe a postprocedure course of clopi-
dogrel therapy (ie, CLASSICS trial3).
Since some of these stents are also com-
posed of nitinol (ie, Scimed Radius stent,
Boston Scientific, Boston, Mass), the man-
agement of a patient with an aortic connec-
tor should be no different from the docu-
mented protocol well described in the
cardiology literature.
To date we have not experienced any
complications with the aforementioned
aortic connector and agree with the authors
that the 2 cases that they described
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involved patients with complex disease and
other mitigating factors. We therefore con-
tinue not only to use the connector but to
promote its use to our colleagues.
R. L. Quigley, MD, PhD
Division of Cardiothoracic Surgery
Albert Einstein Medical Center
Philadelphia, PA 19141
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Reply to the Editor:
Since submission of our report, we too
have begun to administer clopidogrel rou-
tinely, 75 mg by mouth every morning
starting on the first postoperative morning
and continuing through the second postop-
erative month. We have detected no new
problems.
Baron Hamman, MD
Division of Cardiovascular Surgery
Baylor University Medical Center
Dallas, TX 75246
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Symmetry aortic connector system
To the Editor:
The article by Donsky and colleagues1 re-
garding thrombotic occlusion of vein grafts
after use of the Symmetry aortic connector
system (St Jude Medical, Inc, St Paul,
Minn) aroused my interest because of my
experience with this device. Similar to the
authors’ experience, I have had occlusion
of the aortic orifice at the connector site
within a few months of surgery in 3 pa-
tients. All patients were obese, diabetic,
and hypertensive, as in the patients refer-
enced in the article. It has been my expe-
rience, however, that these occlusions oc-
cur when a small (gray) connector is used,
but not when a large (blue or purple) con-
nector can be used. The authors do not
mention the size of the connectors used in
their case report. I would like to ask their
opinion regarding my observation.
Terrill E. Theman, MD
701 Ostrum St, Suite 201
Bethlehem, PA 18015
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Reply to the Editor:
Size of the connector was not recorded in
the permanent record.
Baron Hamman, MD
Division of Cardiovascular Surgery
Baylor University Medical Center
Dallas, TX 75246
doi:10.1067/mtc.2003.285
Does normothermic cardiopulmonary
bypass influence clinical outcomes,
cytokine production, and in vitro
platelet function?
To the Editor:
We read with great interest the article by
Gaudino and associates1 in the June 2002
issue of this Journal. They evaluated pro-
spectively the clinical outcomes of pa-
tients and some inflammatory and fi-
brinolytic markers such as C-reactive
protein, interleukin (IL) 6, prothrombin
time, and platelets. They concluded that
normothermic systemic perfusion did not
influence the clinical course or the extent
of inflammatory and hemostatic activa-
tion in patients undergoing primary iso-
lated coronary artery bypass. The mark-
ers were determined before surgical
inetervention; 21, 48, and 72 hours thereaf-
ter; and at hospital discharge.
We2 previously investigated platelet ac-
tivation and aggregation up to 24 hours
after operation by examining the serial
changes of platelet count and small particle
formation in patients undergoing coronary
artery bypass with normothermic cardio-
pulmonary bypass (CPB). Platelet counts
decreased during CPB, and 24 hours after
CPB they had increased to approximately
half the pre-CPB levels. Small particle for-
mation was the main type of platelet aggre-
gation observed before surgery. Medium
particle formation was also recognized, but
no patient had large particle formation. Af-
ter systemic heparinization, small and me-
dium particle formation occurred. One
hour after the initiation of CPB, only small
particles were seen; 2 hours after the end of
CPB, no small particles were observed.
Small particle formation was the main
platelet aggregation type observed 24 hours
after CPB.
We3 also evaluated cytokine production
and levels of thrombomodulin and soluble
endothelium-derived adhesion molecules
in patients undergoing coronary artery by-
pass under normothermic CPB. The study
was scheduled also up to 24 hours after the
operation. IL-6 values were elevated min-
imally after 30 minutes of CPB, and they
showed a surge at the end of CPB or 2
hours after CPB in some patients. Other
patients showed stable levels. The IL-6 val-
ues were reduced after 2 hours, but 24
hours after CPB they were still higher than
the initial levels. There was a huge differ-
ence in IL-6 changes among patients. A
surge of IL-8 occurred 2 hours after CPB,
and the values returned to the initial levels
24 hours after CPB. Thrombomodulin lev-
els were reduced 30 minutes after the ini-
tiation of CPB; however, they began to
recover during CPB. The levels returned to
the initial levels 2 hours after CPB and
exceeded them 24 hours after CPB. Levels
of soluble endothelium-derived adhesion
molecules were reduced after 30 minutes of
CPB; they returned to the initial levels 2
hours after CPB and exceeded them 24
hours after CPB.
Our studies may endorse the conclu-
sions of Gaudino and associates. CPB for
less than 3 hours does not influence clinical
outcomes, and in vitro studies, such as
platelet function and cytokine production,
did not differ under normothermic and
moderate hypothermic conditions.
Yoshio Misawa, MD
Katsuo Fuse, MD
Division of Cardiovascular Surgery
Jichi Medical School
3311-1 Yakushiji, Minami-kawachi
Tochigi, 329-0498, Japan
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